搜尋結果
At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improve lives.
We’re calling all aspiring world-class scientists who want to be a part of cutting-edge work to save and improve lives. Explore the possibilities. At Merck, we follow the science. Learn about Merck's research and products by getting to know the science, strategy and brains behind the innovations.
2024年9月26日 · Merck’s (NYSE: MRK) Q1 2024 results reflect continued strong growth in oncology and vaccines. Our company announced Q1 worldwide sales of $15.8 billion, an increase of 9% from Q1 2023. “Merck has begun 2024 with continuing momentum in our business.
What we do. We use the power of leading-edge science to save and improve lives around the world. Learn more. Merck aspires to be the premier research-intensive biopharmaceutical company in the world. Learn about our commitment to save and improve lives.
Explore current job opportunities at Merck. Learn more about careers in Business Support, Clinical, Engineering, Information Technology, Research & Development, Manufacturing and Marketing.
We run to, not from, the world’s biggest health challenges. From developing innovations for some of the world’s most debilitating diseases, to getting our medicines and vaccines to those who depend on us and helping to strengthen health systems, we’re always on a mission to create a better world.
2023年12月31日 · At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines.
The first Merck Manual was published in 1899. Treatments in the first manual included bloodletting for acute bronchitis, arsenic for impotence and almond bread for diabetes. The Merck Manual went on to become one of the most widely used medical references.
Advancing innovative science to protect and improve health. We’re a global health care company working to deliver innovative health solutions through our medicines, vaccines, biologic therapies and animal health products. We’re focused on discovering new solutions for today and the future.
2024年5月29日 · Acquisition includes Restoret™, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration, as well as a preclinical pipeline targeting retinal diseases. Restoret anticipated to enter pivotal study for diabetic macular edema in the second half of 2024.
